美通社

2025-02-25 08:00

AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.

Another Step Forward in Global Expansion

HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug Administration (FDA). Not long ago, its mRNA RSV vaccine was also submitted for U.S. clinical trials. In just one month, AIM has made rapid progress in the global rollout of two major mRNA vaccine products.

Why have AIM's multiple mRNA vaccines been able to push for FDA approval in such a short time? First, innovation is in AIM's DNA. The mRNA shingles vaccine, currently submitted for U.S. clinical trials, possesses a high level of technological innovation, ensuring superior vaccine quality. According to the announcement, preclinical animal trials conducted by third-party testing units showed that the specific T cell immunity, specific IgG antibody titers, and fluorescent antibody (FAMA) titers of the mRNA shingles vaccine were significantly higher than those of internationally marketed recombinant subunit control vaccines.

More importantly, with the support of the booming DeepSeek, AIM's mRNA vaccine development is poised to leverage foreseeable leading advantages for rapid advancement. On February 23, AIM announced its comprehensive deployment of the DeepSeek large model, promoting its R1 version through localized strategies for application across all business scenarios, aiming to achieve "cost reduction, quality improvement, and efficiency enhancement" throughout the vaccine's entire lifecycle. Specifically, to build an intelligent vaccine research and development system, AIM will utilize the DeepSeek large model to discover, design, and manufacture better candidate vaccines.

Additionally, AIM boasts a strong accumulation of experience and first-mover advantage in its mRNA technology platform. As one of the earliest companies to develop mRNA vaccine products in China, AIM has streamlined the entire lifecycle processes of mRNA vaccine R&D and production, enabling rapid industrialization of mRNA vaccine products following clinical completion, thus accelerating the commercialization process.

As noted in a recent research report by Fosun International Securities, the mRNA platform successfully validated during the COVID-19 pandemic has laid a solid foundation for future growth in both domestic and international markets. The company ensures product quality stability and supply reliability through GMP-certified high-standard production facilities, further solidifying its competitive market position. Multiple major mRNA products, including the mRNA shingles vaccine, mRNA RSV vaccine, and mRNA influenza vaccine, can leverage the company's leading position in next-generation vaccine technology for rapid commercialization.

In summary, the research report from Fosun International Securities indicates that AIM Vaccine, with its differentiated technological advantages and comprehensive product layout, not only shows significant leading potential in the domestic market but also has broad prospects for expansion in international markets, positioning itself to occupy an important place in the global vaccine market.

In just one month, the two major mRNA vaccine products under development have opened the door to the U.S. FDA. AIM's technological innovation strength and its steps toward the international market are accelerating rapidly.

source: AIM Vaccine

送禮活動浪接浪!想緊貼著數活動消息?即Like etnet Facebook專頁!► 立即讚好

人氣文章
最近7天
1
關稅戰 | 特朗普單方面宣稱,與中國簽署一項貿易協議
2
定期存款 | 一周定存合集,港元拆息回升多間銀行加息,恒生兌換外幣7日10厘優惠倒數最後兩天
3
關稅戰 | 特朗普宣布中止美加貿易談判,威脅加徵新關稅
4
美股收盤 | 道指升逾430點,納指與標普500指數創新高
5
定期存款 | 一周定存合集,PAObank開戶定存優惠1個月最高達16厘,大眾推額外定存優惠
6
高息定存 | PAObank推港元定存優惠,1個月最高達16厘
7
港匯續弱金管局四度承接港元沽盤,分析料未來數日再入市干預
8
美參院通過大而美法案,避險需求提振金價,紫金分拆國際業務上市看高一線?
9
陸叔專訪 | 恒指上望27000,鎮倉之寶有滙控、內銀及⋯⋯(有片)
10
關稅戰 | 特朗普宣布與越南達成貿協,轉口貨徵稅40%劍指中國
11
定期存款 | 一周定存合集,港元拆息回升本周多家銀行加存息,建行亞洲3個月最高6.88厘
12
橙天嘉禾︰4間影城租約本月29日終止,將停止在港經營影城業務
13
美股收盤 | 道指收市升275點,納指與標普續創新高
14
關稅戰 | FOCUS | 關稅大戲二度延期,新稅率藏對華「毒餌」
15
港股 | 蕭猷華:恒指大漲小回格局不變
16
阿里 | 發零息可轉債可換阿里健康股份,兩股齊走弱應如何部署?
17
神州經脈 | 張一鳴成中國首富,十多地換車國補暫停,股匯齊揚
18
英皇債務違約中小型地產商資產惹關注,分析指港銀風險水平仍安全
19
東莞:激活夜間消費動能,對酒吧等駐唱駐演應批盡批
20
定期存款 | 恒生加6個月港元定存息,天星一年期加至2.15厘
21
美股收盤 | 特朗普關稅威脅引發市場憂慮,道指跌近280點
22
仲量聯行曾煥平:中小型發展商債務危機不容忽視,住宅成「唯一提款機」(有片)
23
定期存款 | 拆息回升多家銀行加定存息,招商永隆6個月1.9厘
24
關稅戰 | 特朗普公布第二批關稅信函,巴西被徵報復性50%高額
25
銀髮理財 | 破解年金三大迷思!年金自製長糧免坐食山崩
26
俄烏 | 白宮威脅對俄徵百分百二級關稅,中國和印度被點名
27
關稅戰 | 美重徵巴西關稅限制擴張部署,比亞迪創近三月低已屆吸納時?
28
關稅戰 | 大幅提高巴西關稅「無肉食」,美國人要捱貴價漢堡包
29
水泥股 | 西藏雅魯藏布江水電工程動工,水泥股獲券商唱好齊飆升仍可追入?
30
港股 | 蕭猷華:科技股料接力支撐大巿
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet Bonus】賞你利嘉敏親筆簽名新書《逆齡生活日常》(價值HK$168)

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

大國博弈

關稅戰

貨幣攻略

說說心理話

Watch Trends 2025

北上食買玩

Wonder in Art

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老